title: The expression of DeltaNTP73, TATP73 and TP53 genes in acute myeloid leukaemia is associated with recurrent cytogenetic abnormalities and in vitro susceptibility to cytarabine cytotoxicity.
abstract: TP73 encodes for two proteins: full-length TAp73 and DeltaNp73, which have little transcriptional activity and exert dominant-negative function towards TP53 and TAp73. We compared TATP73 and DeltaNTP73 expression in acute myeloid leukaemia (AML) samples and normal CD34(+) progenitors. Both forms were more highly expressed in leukaemic cells. Amongst AML blasts, TATP73 was more expressed in AML harbouring the recurrent genetic abnormalities (RGA): PML-RARA, RUNX1-RUNX1T1 and CBFB-MYH11, whereas higher DeltaNTP73 expression was detected in non-RGA cases. TP53 expression did not vary according to DeltaNTP73/TATP73 expression ratio. Leukaemic cells with higher DeltaNTP73/TATP73 ratios were significantly more resistant to cytarabine-induced apoptosis.
authors.affiliation: Haematology Division of the Department of Internal Medicine, Centre for Cell Based Therapy, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.
authors.forename: Antonio R
authors.initials: AR
authors.lastname: Lucena-Araujo
authors.forename: Rodrigo A
authors.initials: RA
authors.lastname: Panepucci
authors.forename: Guilherme A S
authors.initials: GA
authors.lastname: dos Santos
authors.forename: Rafael H
authors.initials: RH
authors.lastname: Jácomo
authors.forename: Bárbara A A
authors.initials: BA
authors.lastname: Santana-Lemos
authors.forename: Ana S G
authors.initials: AS
authors.lastname: Lima
authors.forename: Aglair B
authors.initials: AB
authors.lastname: Garcia
authors.forename: Amélia G
authors.initials: AG
authors.lastname: Araújo
authors.forename: Roberto P
authors.initials: RP
authors.lastname: Falcão
authors.forename: Eduardo M
authors.initials: EM
authors.lastname: Rego
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D002869:Chromosome Aberrations; D003561:Cytarabine / Q000627:therapeutic use*; D004268:DNA-Binding Proteins / Q000235:genetics*; D019008:Drug Resistance, Neoplasm; D015870:Gene Expression; D015321:Gene Rearrangement; D016158:Genes, p53 / Q000235:genetics*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics*; D009687:Nuclear Proteins / Q000235:genetics*; D016133:Polymerase Chain Reaction; D012008:Recurrence; D025521:Tumor Suppressor Proteins / Q000235:genetics*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004268:DNA-Binding Proteins; D009687:Nuclear Proteins; D025521:Tumor Suppressor Proteins; D003561:Cytarabine